NIAID provides research funding and resources for the scientific community to facilitate the development of vaccines, therapeutics, and diagnostics for infectious diseases, including those caused by coronaviruses.
Highlights
NIAID COVID-19 Strategic Research Plan
The NIAID Strategic Plan for COVID-19 Research details the institute’s priorities for controlling and ultimately ending the spread of the novel coronavirus (SARS-CoV-2) and the disease it causes (COVID-19). The plan focuses on four key research areas to accomplish this.
Next Generation COVID-19 Vaccines
NIAID plans to leverage existing infrastructure and network sites to implement a structured program evaluating up to 10 next generation COVID-19 vaccines in Phase 1 and Phase 2 clinical trials.
Antiviral Program for Pandemics
NIAID’s research program to develop safe and effective antivirals to combat SARS-CoV-2 will also build sustainable platforms for targeted drug discovery and development of antivirals against viruses with pandemic potential.
Support for Research
Resources for Researchers
NIAID offers resources such as technologies available for licensing or collaboration, computer applications, and other tools and services to the general scientific community to advance basic, preclinical, and clinical research. See all resources for coronavirus researchers.
For researchers developing products such as diagnostics, vaccines, or drug therapies, NIAID provides repositories, genomics and bioinformatics services and tools, preclinical studies, and clinical evaluation that support each stage of the product development pathway. Read more about NIAID's support for infectious disease product developers.
Also, visit the NIH COVID-19 website for additional resources from other NIH Institutes and Centers.
Funding Information
- To find grant funding opportunities specific to COVID-19, search for COVID on our Opportunities page.
- You may consider other funding opportunities that allow you to propose COVID-19 research, for example, Parent Program Announcements.
- To find all NIAID contract funding opportunities, see contract solicitations.
For the latest information, read recent NIAID Funding News articles.
You can also check out special announcements that will keep you up-to-date on other NIAID-relevant NIH Guide notices.
Data Sharing
Request Access to NIAID COVID-19 Clinical Trials Data Sets
AccessClinicalData@NIAID is an NIAID cloud-based, secure data platform that enables sharing of and access to data sets from NIAID COVID-19 clinical trials for the basic and clinical research community. Read more about AccessClinicalData@NIAID.
Other Opportunities for Shared Data
The Seattle Structural Genomics Center for Infectious Diseases and Center for Structural Genomics of Infectious Diseases are making their data publicly available. See more information about the Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID) in general.
Connect With Other Researchers
The COVID-19 Scientific Interest Group was created to promote collaboration and facilitate the exchange of information and resources among NIH intramural scientists and their HHS colleagues concerning research on COVID-19 and SARS-CoV-2.
Search for scientists at NIAID who research coronaviruses in the scientist directory.
Search for scientists funded by NIAID who research coronaviruses on RePORTER.
Biosafety Information
NIH currently recommends that laboratories working with SARS-CoV-2 adhere to the Centers for Disease Control and Prevention (CDC) interim laboratory biosafety guidelines for collecting and handling specimens potentially containing SARS-CoV-2. In addition, all research subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) must be reviewed and approved by an Institutional Biosafety Committee (IBC).
Get additional information about the NIH Guidelines and IBCs.
Questions related to the NIH Guidelines may be addressed to NIHGuidelines@od.nih.gov.
Immune Response to COVID-19
NIAID researchers are spearheading a large, international collaboration to investigate the innate and adaptive immune responses during acute COVID-19 infection and convalescence. The overall goal is to identify immunological and virological correlates and predictors of clinical outcomes. Researchers are currently seeking physicians to collaborate.